(bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
AssigneeYeda Research and Development Co. Ltd.
InventorsAvigdor SCHERZ, Yoram SALOMON, Arie MARCOVICH, Alexander BRANDIS, Daniel WAGNER
Life of this patent
Estimating the term…
Abstract
An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.
Claims26
A chlorophyll or bacteriochlorophyll compound for use in photodynamic therapy (PDT) of diseases, disorders and conditions associated with corneal or scleral anomaly.
The pharmaceutical composition according claim 14 or 35, further comprising a viscous agent for enhancing the viscosity of the formulation and restricting penetration of the chlorophyll or bacteriochlorophyll compound into the cornea.
The pharmaceutical composition according claim 14 or 35, further comprising a transepitheliai permeability enhancer for enhancing the penetration of the chlorophyll or bacteriochlorophyll compound through the epithelium.
The pharmaceutical composition according to any one of clams 14-20, for use in the photodynamic therapy before local irradiation of the eye with fight at a red or near infrared (NIR) wavelength.
A method for photodynamic therapy of corneal thinning comprising the steps of:
- (a) administering to an individual afflicted with corneal thinning chlorophyll or bacteriochlorophyll compound according to any one of claims 1 to 13, or a pharmaceutical composition according to any one of claims 14 to 22;
- and (b) irradiating the eye with light at a red or near infrared (NIR) wavelength.
A method for preventing a corneal and/or scleral disease or weakening before, during or after interventional procedures, comprising the steps of:
- (a) administering to an individual expected to be afflicted with corneal and/or scleral disease or weakening, a chlorophyll or bacteriochlorophyll compound according to any one of claims 1 to 13, or a pharmaceutical composition according to any one of claims 34 to 22;
- and (b) irradiating the eye with light at a red or near infrared (NIR) wavelength.
Dependencies are inferred from the claim text.